Section 12.2 (Part 3)
Table 12.3 Requirements for conventional blood typing reagents - continued| Antibody specificity | Specification | Performance evaluation
As a minimum, two examples of the following reference cells should be included* | Batch release testing |
|---|
| Specificity | Potency |
|---|
| Positive reactors | Negative reactors |
|---|
| Cell type | No. | Cell type | No. | Cell type | No. |
|---|
| Anti-K | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | Kk Kp (a+b-) | Kk | 4 | kk | 4 | Kk | 2 |
| Kk Kp (a-b+) |
| Anti-k | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | K+k+Kp(a+) | Kk | 4 | KK | 4 | Kk | 2 |
| Kk Kp(a-) | 2 | | | | |
| Kk | 2 | | | | |
| Kk Kp(a+b+) | | | | | |
| Anti-Fya | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | Fyx | Fy(a+b+) | 4 | Fy(a-) | 4 | Fy(a+b+) | 2 |
| Anti-Fyb | Normally clear coloured Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | | Fy(a+b+) | 4 | Fy(b-) | 4 | Fy(a+b+) | 2 |
| Anti-Jka | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | | Jk(a+b+) | 4 | Jk(a-) | 4 | Jk(a+b+) | 2 |
| Anti-Jkb | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | | Jk(a+b+) | 4 | Jk(b-) | 4 | Jk(a+b+) | 2 |
| Anti-S | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | SS,Ss,ss | Ss | 4 | ss | 4 | Ss | 2 |
| Anti-s | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | | Ss | 4 | SS | 4 | Ss | 2 |
| Anti-M | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | NN He+ | MN | 4 | NN | 4 | MN | 2 |
| Anti-N | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | | MN | 4 | MMS | 4 | MN | 2 |
| Anti-P1 | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | | P1 strong | 4 | P1(-) | 4 | P1(+) | 2 |
| P1 weak | 4 | | | | |
| Anti-Lea | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | | Le(a+b-) | 4 | Le(a-) | 4 | Le(a+) | 2 |
| Anti-Leb | Normally clear coloured
Potency titre greater than 4 vs by techniques detailed in the manufacturer's instructions for use
Should detect variants and subgroups as detailed in the manufacturer's instructions for use | A1B Le(a-b+) | A1B Le(a-b+) | 4 | Le(b-) | 4 | A1B Le(b+) | 2 |
* For reagents where reactivity against the antigen is claimed